期刊文献+

慢性心力衰竭患者血浆尾加压素Ⅱ水平的变化及其临床意义 被引量:1

Change of Plasma Urotensin in Patients with Chronic Heart Failure
原文传递
导出
摘要 目的本文旨在研究尾加压素Ⅱ(urotensinⅡ,UⅡ)在慢性心力衰竭患者中含量变化及其临床意义。方法入选20例正常人(对照组)、88例心力衰竭患者(心力衰竭组:心功能Ⅱ级23例、Ⅲ级29例、Ⅳ级36例)为研究对象,采用放射免疫分析法测定血浆UⅡ浓度,竞争酶免疫分析法测定血浆BNP浓度,超声心动图测定左室射血分数(EF)、左室质量指数(LVMI)等参数。结果正常对照组和心力衰竭组间年龄、性别等基线资料无明显差异;心力衰竭组血浆UⅡ浓度显著低于正常对照组(分别为3.45±0.97 pg/ml和5.73±0.69 pg/ml,P<0.001),而血浆BNP浓度显著高于正常对照组(分别为512±233pg/ml和65±26pg/ml,P<0.001);血浆UⅡ浓度与LVEF呈显著正相关(r=0.62,P<0.001),与血浆BNP浓度呈显著负相关(r=-0.79,P<0.01),与左心室质量指数(LVMI)显著负相关(r=-0.36,P<0.01)。结论慢性心力衰竭患者血浆UⅡ浓度显著降低,并且与左室射血分数正相关,左心室质量指数负相关。 Objective To compare plasma urotensin Ⅱ( UⅡ) concentration in patients with chronic heart failure(CHF) and healthy control, and to explore its clinical significance. Methods Eighty-eight patients with CHF and 20 healthy controls were enrolled in the study. Plasma concentration of UⅡ were measured by radioimmunoassay. BNP were measured by enzyme-linked immunosorbent assay. Left ventricular ejection fraction and Left ventricular mass index were measured by echocardiography. Results There were no difference in sex and age between healthy controls and CHF patients. Plasma concentration of UⅡ in CHF group was significant lower than healthy group(3.45±0.97 pg/ml vs.5.73±0.69 pg/ml, P0.001), and plasma BNP level was significant higher than healthy group(512±233pg/ml vs. 65±26pg/ml, P0.001). Plasma UⅡ concentration was correlated with LVEF(r=0.62, P0.001). Plasma U Ⅱ concentration was correlated with BNP(r=-0.79, P0.001). Also Plasma U Ⅱconcentration was correlated with LVMI(r=-0.36, P0.01). Conclusion Plasma UⅡ concentration was decreased significantly in chronic heart failure patients. The levels of plasma UⅡ were correlated with abnormal LVEF and LVMI, which may have a clinical significance to early diagnosis and evaluated treatment efficacy of CHF.
出处 《中国分子心脏病学杂志》 CAS 2014年第4期1004-1006,共3页 Molecular Cardiology of China
关键词 尾加压素Ⅱ 心力衰竭 左室射血分数 Urotensin Ⅱ Chronic Heart Failure Ejection Fraction
  • 相关文献

参考文献12

  • 1Conlon JM, Yano K, Waugh D, et al Distribution and molecular fon-s of urotensin Ⅱ and its role in cardiovascular regulation in vertebrates. J Exp Zool. 1996,275:226-238.
  • 2Ames RS, Sarau HM, Chambers JK, et al. Human urotensin Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPRI4. Nature. 1999,401:282-286.
  • 3Zemancikova A, Torok J. Urotensin Ⅱ -a newly discovered modulator of cardiovascular functions in vertebrates. Cesk Fysiol. 2013,62(1 ): 19- 25.
  • 4Ross B, Mckendy K, Giaid A. Role of urotensin Ⅱ in health and disease. Am J Physiol Regul Integr Comp Physiol. 2010;298(5):R1156-72.
  • 5无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3675
  • 6De las Fuentes L, Brown AL, Mathews S J, et al. Metabolic syndrome is associated with abnormal left ventricular diastolicfunction independent of left ventricular mass. 2007;28(5):553-9.
  • 7Leong L, Ian Loke, Russel J. Plasma urotensin systolic heart failure. Circulation. 2002; 106:2877.
  • 8Eur Heart J Ⅱ in human Jolda-Mydlowska B, Salmon P, Mazurek W. Plasma urotensin H level in patients with chronic congestive heart failure. Pol Arch Med Wewn. 2006; 116(6): 1125-36.
  • 9Kruger S, Graf J, Kunz D. Urotensin Ⅱ in patients with chronic heart failure. Eur J Heart Fail. 2005;7(4):475.
  • 10Dschietzig T, Richter C, Bartsch C, et al. Flow-induced pressuredifferentially regulates endothelin-1, arotensinⅡ, adrenomdullin, and relaxin in pulmonary vascular endothelium. Biochem Biophys Res Commun. 2001,289(1):245.

二级参考文献42

  • 1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:90
  • 2Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
  • 3Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
  • 4Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
  • 5Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
  • 6Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol, 2006, 22 (1): 23-45.
  • 7Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail, 2006, 12 ( 1 ) : e1-2.
  • 8Enright PL, Sherrill DL Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med, 1998, 158(5 pt 1) :1384-1387.
  • 9Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J, 1999, 14(2) : 270-274.
  • 10Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation, 2002, 105 (20):2328-2331.

共引文献3674

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部